Home  /  Resource Library  /  Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

ASH 2020: Initial results of a phase II study investigating Azacitidine combined with chemotherapy for first line treatment of peripheral t-cell lymphomas.